Vignesh K Alamanda1, Myra M Robinson2, Jeffrey S Kneisl3, Joshua C Patt3. 1. Department of Orthopaedic Surgery, Carolinas Medical Center, Charlotte, NC, USA. 2. Department of Cancer Biostatistics, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA. 3. Department of Orthopaedic Surgery, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
Abstract
BACKGROUND: Retrospective review of a prospective database. Spine metastasis has been shown to occur in 40% of cancer patients with an annual incidence of over 18,000 cases in North America alone. In this study, we sought to explore the functional and survival outcomes of patients undergoing surgical treatment for metastatic disease of the spine. METHODS: A retrospective cohort study of a prospective database at a major cancer center was conducted. A total of 55 patients who met the inclusion criteria from January 2010 to December 2015 were included. Functional status was assessed through patient's ambulatory status. Patient and tumor characteristics were analyzed and regression analyses were performed. RESULTS: Renal cell carcinoma (RCC) was the most common subtype encountered (27.3%). Excluding patients who had spinal metastasis at time of diagnosis, the median time to spinal metastasis from cancer diagnosis was 2.5 years. Median overall survival (OS) time was 1.8 years post diagnosis and 1.6 years post-surgical intervention. Age and tumor subtype were independent predictors of death (P<0.05). Post-surgical intervention, only 3.6% of patients were unable to ambulate-an improvement from 12.7% seen in the immediate preoperative period, P=0.0253. However, at the time of final follow-up, this number had risen to nearly 37%, P<0.0001. CONCLUSIONS: Spinal metastasis portends a debilitating prognosis. Ambulatory status is improved or maintained in the post-surgical period. However, long-term outlook remains dismal with median survival at only 1.8 years following diagnosis of spinal metastasis and ambulatory status declining precipitously at the time of final follow-up.
BACKGROUND: Retrospective review of a prospective database. Spine metastasis has been shown to occur in 40% of cancer patients with an annual incidence of over 18,000 cases in North America alone. In this study, we sought to explore the functional and survival outcomes of patients undergoing surgical treatment for metastatic disease of the spine. METHODS: A retrospective cohort study of a prospective database at a major cancer center was conducted. A total of 55 patients who met the inclusion criteria from January 2010 to December 2015 were included. Functional status was assessed through patient's ambulatory status. Patient and tumor characteristics were analyzed and regression analyses were performed. RESULTS: Renal cell carcinoma (RCC) was the most common subtype encountered (27.3%). Excluding patients who had spinal metastasis at time of diagnosis, the median time to spinal metastasis from cancer diagnosis was 2.5 years. Median overall survival (OS) time was 1.8 years post diagnosis and 1.6 years post-surgical intervention. Age and tumor subtype were independent predictors of death (P<0.05). Post-surgical intervention, only 3.6% of patients were unable to ambulate-an improvement from 12.7% seen in the immediate preoperative period, P=0.0253. However, at the time of final follow-up, this number had risen to nearly 37%, P<0.0001. CONCLUSIONS: Spinal metastasis portends a debilitating prognosis. Ambulatory status is improved or maintained in the post-surgical period. However, long-term outlook remains dismal with median survival at only 1.8 years following diagnosis of spinal metastasis and ambulatory status declining precipitously at the time of final follow-up.
Authors: David Choi; A Crockard; C Bunger; J Harms; N Kawahara; C Mazel; R Melcher; K Tomita Journal: Eur Spine J Date: 2009-12-29 Impact factor: 3.134
Authors: Jonathan N Sellin; Dima Suki; Viraat Harsh; Benjamin D Elder; Daniel K Fahim; Ian E McCutcheon; Ganesh Rao; Laurence D Rhines; Claudio E Tatsui Journal: J Neurosurg Spine Date: 2015-07-03
Authors: Cyrus M Jalai; Nancy Worley; Bryan J Marascalchi; Vincent Challier; Shaleen Vira; Sun Yang; Anthony J Boniello; John A Bendo; Virginie Lafage; Peter G Passias Journal: Spine (Phila Pa 1976) Date: 2016-02 Impact factor: 3.468
Authors: Miao Wang; Cody Eric Bünger; Haisheng Li; Chunsen Wu; Kristian Høy; Bent Niedermann; Peter Helmig; Yu Wang; Anders Bonde Jensen; Katrin Schättiger; Ebbe Stender Hansen Journal: Spine (Phila Pa 1976) Date: 2012-04-01 Impact factor: 3.468
Authors: L Bollen; G C W de Ruiter; W Pondaag; M P Arts; M Fiocco; T J T Hazen; W C Peul; P D S Dijkstra Journal: Eur Spine J Date: 2013-03-02 Impact factor: 3.134
Authors: Z L Gokaslan; J E York; G L Walsh; I E McCutcheon; F F Lang; J B Putnam; D M Wildrick; S G Swisher; D Abi-Said; R Sawaya Journal: J Neurosurg Date: 1998-10 Impact factor: 5.115
Authors: Grace X Xiong; Miles W A Fisher; Joseph H Schwab; Andrew K Simpson; Lananh Nguyen; Daniel G Tobert; Tracy A Balboni; John H Shin; Marco L Ferrone; Andrew J Schoenfeld Journal: Spine (Phila Pa 1976) Date: 2022-04-01 Impact factor: 3.468